ICU Medical Inc
$ 142.20
-0.46%
12 Jun - close price
- Market Cap 3,554,088,000 USD
- Current Price $ 142.20
- High / Low $ 144.04 / 141.12
- Stock P/E 76.45
- Book Value 84.50
- EPS 1.86
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 160.29
- 52 Week Low 107.00
About
ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.
Analyst Target Price
$172.86
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.49 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ICUI
2026-06-12 15:38:58
ICU Medical, Inc. (ICUI), a medical device company specializing in infusion therapy, has been highlighted by Madison Small Cap Fund as a new position. The company is gaining market share due to quality issues faced by competitors Becton Dickinson (BDX) and Baxter (BAX), and its new high-volume pump with connected features is expected to drive retention and incremental revenue. Despite a recent market underperformance, the fund views ICUI as well-positioned in a volatile market with a valuation of 12x EBITDA, estimating its intrinsic value at approximately $200/share.
2026-06-11 00:08:50
ICU Medical's General Counsel, Virginia Ruth Sanzone, sold 2,447 shares of company stock for approximately $304,000. This sale represents Sanzone's largest direct sale in the last year, reducing her holdings by over 11%. The article questions whether ICU Medical is a worthwhile investment, emphasizing the ongoing challenges of the Smiths Medical integration and significant debt against a backdrop of rising interest rates and tariff headwinds.
2026-06-08 20:09:26
ICU Medical Inc recently reported its latest quarterly figures and is continuing the integration of its Smiths Medical acquisition, while managing a mixed demand and margin environment. The article details the company's core business model, key revenue and product drivers, and what its numbers and guidance mean for investors. It notes ICU Medical's focus on infusion therapy, oncology, and critical care products, highlighting its recurring revenue model from disposable components and its strategic contracts with healthcare organizations.
2026-06-08 17:09:46
Norges Bank has made a new $58.08 million investment in ICU Medical, acquiring 407,115 shares and now owning approximately 1.65% of the company. This comes as ICU Medical reported quarterly earnings that beat expectations, with EPS of $1.97, despite a 12.3% year-over-year revenue decrease. The stock currently holds a "Buy" consensus rating from analysts, with an average price target of $168.
2026-06-04 22:34:00
This article provides a detailed analysis of Icu Medical Inc. (ICUI) focusing on risk zones and trading strategies based on AI models. It highlights conflicting sentiment across different time horizons, suggesting choppy conditions, and offers specific position trading, momentum breakout, and risk hedging strategies with entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strength, support, and resistance levels for the stock.
2026-06-04 08:13:19
ICU Medical Inc. (ICUI) is currently considered undervalued, with its fair price estimated to be between $168.98 and $254.95, compared to its current price of $130.52. Despite this, its P/S ratio of 1.43 is significantly above the industry average, which, coupled with a -12.32% revenue growth, suggests this premium may be unsustainable. The article provides detailed valuation metrics such as P/B ratio, FCF yield, and forward P/E and P/S ratios to support this assessment.
